374 related articles for article (PubMed ID: 15896094)
21. Patient preferences for depression treatment programs and willingness to pay for treatment.
Morey E; Thacher JA; Craighead WE
J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
[TBL] [Abstract][Full Text] [Related]
22. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
Byrne MM; O'malley K; Suarez-Almazor ME
Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
[TBL] [Abstract][Full Text] [Related]
23. Willingness to pay in the context of an economic evaluation of healthcare programs: theory and practice.
Gafni A
Am J Manag Care; 1997 May; 3 Suppl():S21-32. PubMed ID: 10180338
[TBL] [Abstract][Full Text] [Related]
24. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.
Baker R; Bateman I; Donaldson C; Jones-Lee M; Lancsar E; Loomes G; Mason H; Odejar M; Pinto Prades JL; Robinson A; Ryan M; Shackley P; Smith R; Sugden R; Wildman J;
Health Technol Assess; 2010 May; 14(27):1-162. PubMed ID: 20525460
[TBL] [Abstract][Full Text] [Related]
25. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
Dolan P; Edlin R
J Health Econ; 2002 Sep; 21(5):827-43. PubMed ID: 12349884
[TBL] [Abstract][Full Text] [Related]
26. Capabilities as menus: a non-welfarist basis for QALY evaluation.
Bleichrodt H; Quiggin J
J Health Econ; 2013 Jan; 32(1):128-37. PubMed ID: 23202258
[TBL] [Abstract][Full Text] [Related]
27. Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.
Nielsen JS; Gyrd-Hansen D; Kjaer T
Health Econ; 2021 May; 30(5):923-931. PubMed ID: 33569834
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
[TBL] [Abstract][Full Text] [Related]
29. Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.
Kouakou CRC; He J; Poder TG
Eur J Health Econ; 2024 Jul; 25(5):787-811. PubMed ID: 37656261
[TBL] [Abstract][Full Text] [Related]
30. The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method.
Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
Pharmacoecon Open; 2019 Sep; 3(3):311-319. PubMed ID: 30617954
[TBL] [Abstract][Full Text] [Related]
31. Willingness to pay: a valid and reliable measure of health state preference?
O'Brien B; Viramontes JL
Med Decis Making; 1994; 14(3):289-97. PubMed ID: 7934716
[TBL] [Abstract][Full Text] [Related]
32. Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey.
Franic DM; Pathak DS; Gafni A
J Clin Epidemiol; 2005 Mar; 58(3):291-303. PubMed ID: 15718119
[TBL] [Abstract][Full Text] [Related]
33. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?
Van Houtven G; Powers J; Jessup A; Yang JC
Health Econ; 2006 Aug; 15(8):775-95. PubMed ID: 16544361
[TBL] [Abstract][Full Text] [Related]
34. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
35. The value of a QALY: individual willingness to pay for health gains under risk.
Bobinac A; van Exel J; Rutten FF; Brouwer WB
Pharmacoeconomics; 2014 Jan; 32(1):75-86. PubMed ID: 24293198
[TBL] [Abstract][Full Text] [Related]
36. Estimating a constant WTP for a QALY-a mission impossible?
Sund B; Svensson M
Eur J Health Econ; 2018 Jul; 19(6):871-880. PubMed ID: 28932914
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
Song HJ; Lee EK
Medicine (Baltimore); 2018 Sep; 97(38):e12453. PubMed ID: 30235732
[TBL] [Abstract][Full Text] [Related]
39. Theoretical bounds on the value of improved health.
Herrera-Araujo D; Hammitt JK; Rheinberger CM
J Health Econ; 2020 Jul; 72():102341. PubMed ID: 32531565
[TBL] [Abstract][Full Text] [Related]
40. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies.
Radcliff K; Lerner J; Yang C; Bernard T; Zigler JE
J Neurosurg Spine; 2016 May; 24(5):760-8. PubMed ID: 26824587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
